BioInvest In The News

Top Picks 2016: The Medicines Company (1-28-2016)
Top Picks 2016: Anthera Pharmaceuticals (1-15-2016)
2015's Top Performers (1-12-2016)
2015's Top Performers (12-30-2015)
Biotech Bets: A Mispriced Trio  (11-9-2015)
Life Sciences Report (9-16-15)
Company Updates
Intrexon Update (1-7-16)

Intrexon Update (1-7-16)

Intrexon (XON) – Two Health Care Deals Signed For Metabolic Diseases and RA – The first deal is with Janssen Pharmaceutica NV (JNJ’s Euro Division) is to discover and develop ActoBiotics therapies directed against selected targets to treat Type 2 diabetes (T2D), obesity and/or metabolic disorders related to energy dysregulation. XON’s ActoBiotics platform represents an innovative oral delivery system for biological effectors ideally suited to tackle multiple aspects of T2D with the potential to improve efficacy in maintaining glycemic control in the long term. Read more…

Five Prime Update (1-7-16)

Five Prime Update (1-7-16)

Five Prime (FPRX) – Poised For Big Time 2016; Raising Buy & Target – FPRX had a great year in 2015 with the BMS deal being one of the best we have ever seen for a Phase I compound. The company continues to click on all cylinders and in our view, with the strength and depth of that deal, the Company is gaining further momentum. Early 2016 is ripe with three clinical trials releases that should serve as important catalysts to begin the year. Read more…

Anthera Update (1-07-16)

Anthera Update (1-07-16)

Anthera (ANTH) Strengthens Senior Management With President/COO & Chief Technology Officer – Craig Thompson is joining ANTH as President and Chief Operating Officer. He comes with an experienced Big Pharma strategic marketing background (~10 years at Merck, ~8 at Pfizer), and will oversee both of the Company’s late-stage development programs and commercial preparation efforts. read more…